Tinniwell receives patent in the US
The Resaphene has received the patent grant notice from the US Patent Authority. Now the only tinnitus therapy with proof of efficacy on the market in the two target regions Europe and the US is protected.
Basic Information
| Issuer | Resaphene Suisse AG |
| Board of Directors | Anke Rauterkus (President), Oliver Merz |
| Share capital | 1,100.000 CHF |
| Number of shares | 1,100.000 bearer shares at CHF 1 |
| Year of foundation | 2015 |
| Accounting | Local GAAP |
| Collective deposit | SIX SIS AG, Baslerstrasse 100, CH-4601 Olten |
| Commercial Register Number | CHE-425.422.997 |
| FISN | Resaphene Suis/BrSh CHF 1 |
| ISIN | CH0367465439 |
| WKN | A2JG91 |
| LEI | 8945000JP3FHX87LO121 |
| VAT | CHE-425.422.997 |
| VALOR | CH036746543 |
| Paying Agent | FinTech Group Bank AG, Rotfeder-Ring 7, D-60327 Frankfurt am Main |
Reports
Financial Calendar
09/04/2019 General Assembly
Expansion to North America
In order to launch the Tinniwell in the USA, Resaphene founded the new national company Resaphene US LLC. The responsible director was Thomas Rauterkus. In his area of responsibility is also the approval procedure with the competent authority US Food and Drug Administration.
Resaphene Suisse AG announces patent on tinniwell
Resaphene Suisse AG was informed after the hearing at the European Patent Office about the forthcoming grant of the patent. As a next step, the Board also expects to complete the patent process in the US.
In February 2019, management will introduce tinnitus therapy in the US and drive expansion there. A decision whether a separate national company is founded there or if sales partners are used has not yet fallen.